BRIDGE AD - Building BRidges to BrIng AntiamyloiD Monoclonal Antibodies to EliGible PatiEnts With Alzheimer’s Disease

Target Audience

The educational design of this activity addresses the needs of neurology, radiology, emergency, geriatric, and primary care clinicians, and infusion center staff (physicians, nurse practitioners, physician assistants, nurses, nurses, and administrative staff) who are involved in the management of patients with Alzheimer's Disease (AD).

Program Overview

In this follow-up to the live BRIDGE AD meeting series that discussed implementation tactics and best practices for administration of antiamyloid therapies (AATs), Dr. David Weisman answers common questions related to AATs and reviews the most recent updates in AD. This video covers use of blood-based biomarkers, communication strategies, providing AATs to APOE4 homozygous patients, and the use of SQ AATs for people with early AD.

Educational Objectives

After completing this activity, the participant should be better able to:

• Review the most recent updates in antiamyloid therapy administration, data, and clinic protocols.

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Nurses Credentialing Center’s (ANCC) Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score at least 70% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the ACCME and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

David C. Weisman, MD: Consulting Fees: Biogen Inc., Eisai Inc., Lantheus Holdings, Inc., MapLight Therapeutics, Inc., Novartis Pharmaceuticals Corporation, Viz.ai, Inc.; Fees for Non-CE Services Received Directly From an Ineligible Entity or Their Agents  (eg, speakers’ bureaus): Eisai Inc., Eli Lilly and Company; Contracted Research: Acadia Pharmaceuticals Inc., Acumen Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Alzheimer’s Association, Cerevel Therapeutics, Cognition Therapeutics, Inc., Eisai Inc., Eli Lilly and Company, EMD Serono, Inc., F. Hoffmann-La Roche Ltd, Sage Therapeutics, Inc., Sanofi, Ventus Therapeutics; Other (Regulatory): US Food and Drug Administration (FDA) Peripheral and Central Nervous System Drugs (PCNS) advisory committee.

The planners and managers at Integritas Communications have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integritas does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.